At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 59 enrolled
Drug / intervention
Bexarotenedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma
In Brief
A Phase 4 clinical trial evaluating Bexarotene for Refractory Cutaneous T-cell Lymphoma. Completed, enrolled 59 participants across 17 sites.
Detailed Summary
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Cutaneous T-cell Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartJan 2010
Primary CompletionFeb 2014
TodayJul 2026
First PostedNov 4, 2009
Enrollment StartJan 6, 2010
Primary CompletionFeb 20, 2014
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 16.7 years ago
Interventions
Bexarotenedrug
Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.